Commercially funded and United States-based research is more likely to be published; good-quality studies with negative outcomes are not

Journal of Bone and Joint Surgery

Volumn 89, Issue 5, 2007, Pages 1010-1018

  Lynch, Joseph R ^a   Cunningham, Mary R A ^a   Warme, Winston J ^b   Schaad, Douglas C ^a   Wolf, Fredric M ^a   Leopold, Seth S ^b  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b WILLIAM BEAUMONT ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; FUNDING; MEDICAL LITERATURE; MEDICAL RESEARCH; OUTCOME ASSESSMENT; PEER REVIEW; PRIORITY JOURNAL; PUBLICATION; QUALITY CONTROL;

EID: 34248148475     PISSN: 00219355     EISSN: None     Source Type: Journal    
DOI: 10.2106/JBJS.F.01152     Document Type: Article

References (78)

1. Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA. 2003;290:921-8.
2. Callaham ML, Wears RL, Weber EJ, Barton C, Young G. Positive-outcome bias and other limitations in the outcome of research abstracts submitted to a scientific meeting. JAMA. 1998;280:254-7. Erratum in: JAMA. 1998; 280:1232.
3. Chalmers TC, Frank CS, Reitman D. Minimizing the three stages of publication bias. JAMA. 1990;263:1392-5.
4. Dickersin K. The existence of publication bias and risk factors for its occurrence. JAMA. 1990;263:1385-9.
5. Davidson RA. Source of funding and outcome of clinical trials. J Gen Intern Med. 1986;1:155-8.
6. Dickersin K, Min YI. NIH clinical trials and publication bias. Online J Curr Clin Trials. 1993;Doc No 50:[4967 words; 53 paragraphs].
7. Dickersin K, Min YI, Meinen CL. Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards. JAMA. 1992;267:374-8.
8. Freemantle N, Mason J. Publication bias in clinical trials and economic analyses. Pharmacoeconomics. 1997;12:10-6.
9. Friedberg M, Saffran B, Stinson TJ, Nelson W, Bennett CL. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA. 1999;282:1453-7.
10. Hetherington J, Dickersin K, Chalmers I, Meinert CL. Retrospective and prospective identification of unpublished controlled trials: lessons from a survey of obstetricians and pediatricians. Pediatrics. 1989;84:374-80.
11. Stern JM, Simes RJ. Publication bias: evidence of delayed publication in a cohort study of clinical research projects. BMJ. 1997;315:640-5.
12. Misakian AL, Bero LA. Publication bias and research on passive smoking: comparison of published and unpublished studies. JAMA. 1998;280:250-3.
13. Sharp DW. What can and should be done to reduce publication bias? The perspective of an editor. JAMA. 1990;263:1390-1.
14. Leopold SS, Warme WJ, Fritz Braunlich E, Shott S. Association between funding source and study outcome in orthopaedic research. Clin Orthop Relat Res. 2003;415:293-301.
15. Shah RV, Albert TJ, Bruegel-Sanchez V, Vaccaro AR, Hilibrand AS, Grauer JN. Industry support and correlation to study outcome for papers published in Spine. Spine. 2005;30:1099-105.
16. Ezzet KA. The prevalence of corporate funding in adult lower extremity research and its correlation with reported results. J Arthroplasty. 2003; 18(7 Suppl 1):138-45.
17. Bhandari M, Busse JW, Jackowski D, Montori VM, Schunemann H, Sprague S, Mears D, Schemitsch EH, Heels-Ansdell D, Devereaux PJ. Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. CMAJ. 2004;170:477-80.
18. Bhandari M, Richards RR, Sprague S, Schemitsch EH. The quality of reporting of randomized trials in the Journal of Bone and Joint Surgery from 1988 through 2000. J Bone Joint Surg Am. 2002;84:388-96.
19. Cunningham MR, Warme WJ, Schaad DC, Wolf FM, Leopold SS. Industry-funded positive studies not associated with better design or larger size. Clin Orthop Relat Res. 2006 Dec 28; [Epub ahead of print].
20. Perez EA, Yates AJ. Positive outcomes in the orthopaedic literature. Presented at the annual meeting of the American Academy of Orthopaedic Surgeons; 2000 Mar 15-19; Orlando, FL.
21. Bhandari M, Morrow F, Kulkami AV, Tornetta P 3rd. Meta-analyses in orthopaedic surgery. A systematic review of their methodologies. J Bone Joint Surg Am. 2001;83:15-24.
22. Hurwitz SR, Slawson D, Shaughnessy A. Orthopaedic information mastery: applying evidence-based information tools to improve patient outcomes while saving orthopaedists' time. J Bone Joint Surg Am. 2000;82:888-94.
23. Jackson D. The implications of publication bias for meta-analysis' other parameter. Stat Med. 2006;25:2911-21.
24. Song F, Khan KS, Dinnes J, Sutton AJ. Asymmetric funnel plots and publication bias in meta-analyses of diagnostic accuracy. Int J Epidemiol. 2002; 31:88-95.
25. Sutton AJ, Song F, Gilbody SM, Abrams KR. Modelling publication bias in meta-analysis: a review. Stat Methods Med Res. 2000;9:421-45.
26. Begg CB, Berlin JA. Publication bias and dissemination of clinical research. J Natl Cancer Inst. 1989;81:107-15.
27. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991;337:867-72.
28. Thornton A, Lee P. Publication bias in meta-analysis: its causes and consequences. J Clin Epidemiol. 2000;53:207-16.
29. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA. 2003;289:454-65.
30. Kjaergard LL, Als-Nielsen B. Association between competing interests and authors' conclusions: epidemiological study of randomised clinical trials published in the BMJ. BMJ. 2002;325:249.
31. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003;326:1167-70.
32. Rochon PA, Gurwitz JH, Simms RW, Fortin PR, Felson DT, Minaker KL, Chalmers TC. A study of manufacturer-supported trials of nonsteroidal antiinflammatory drugs in the treatment of arthritis. Arch Intern Med. 1994;154: 157-63.
33. Stelfox HT, Chua G, O'Rourke K, Detsky AS. Conflict of interest in the debate over calcium-channel antagonists. N Engl J Med. 1998;338:101-6.
34. Vickers A, Goyal N, Harland R, Rees R. Do certain countries produce only positive results? A systematic review of controlled trials. Controll Clin Trials. 1998;19:159-66.
35. Guyatt GH, Haynes RB, Jaeschke RZ, Cook DJ, Green L, Naylor CD, Wilson MC, Richardson WS. Users' Guides to the Medical Literature: XXV. Evidence-based medicine: principles for applying the Users' Guides to patient care. Evidence-Based Medicine Working Group. JAMA. 2000;284:1290-6.
36. Guyatt GH, Sackett DL, Cook DJ. Users' guides to the medical literature. II. How to use an article about therapy or prevention. A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA. 1993;270:2598-601.
37. Guyatt GH, Sackett DL, Cook DJ. Users' guides to the medical literature. II. How to use an article about therapy or prevention. B. What were the results and will they help me in caring for my patients? Evidence-Based Medicine Working Group. JAMA. 1994;271:59-63.
38. Jaeschke R, Guyatt G, Sackett DL. Users' guides to the medical literature. III. How to use an article about a diagnostic test. A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA. 1994;271:389-91.
39. Jaeschke R, Guyatt GH, Sackett DL. Users' guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. JAMA. 1994;271:703-7.
40. McAlister FA, Laupacis A, Wells GA, Sackett DL. Users' Guides to the Medical Literature: XIX. Applying clinical trial results B. Guidelines for determining whether a drug is exerting (more than) a class effect. JAMA. 1999; 282:1371-7.
41. Oxman AD, Sackett DL, Guyatt GH. Users' guides to the medical literature. I. How to get started. The Evidence-Based Medicine Working Group. JAMA. 1993; 270:2093-5.
42. Bhandari M, Montori VM, Swiontkowski MF, Guyatt GH. User's guide to the surgical literature: how to use an article about a diagnostic test. J Bone Joint Surg Am. 2003;85:1133-40.
43. Sackett DL, Straus SE, Richardson WS, Rosenberg W, Haynes RB, editors. Evidence-based medicine: how to practice and teach EBM. 2nd ed. Edinburgh: Churchill Livingstone; 2000.
44. Mahoney MJ. Publication prejudices - an experimental study of confirmatory bias in the peer review system. Cognit Ther Res. 1977;1:161-75.
45. JAMA publishes correction on author disclosure for study on antidepressant use during pregnancy, tightens disclosure requirements. Medical News Today. 2006 July 14.
46. Urato AC. Antidepressant treatment and relapse of depression during pregnancy. JAMA. 2006;296:166-7.
47. Flanagin A, Fontanarosa PB, DeAngelis CD. Update on JAMA'S conflict of interest policy. JAMA. 2006;296:220-1.
48. Cohen LS, Altshuler LL, Harlow BL, Nonacs R, Newport DJ, Viguera AC, Suri R, Burt VK, Hendrick V, Reminick AM, Loughead A, Vitonis AF, Stowe ZN. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA. 2006;295:499-507. Erratum in: JAMA. 2006; 296:170.
49. Blumenthal D, Campbell EG, Anderson MS, Causino N, Louis KS. Withholding research results in academic life science. Evidence from a national survey of faculty. JAMA. 1997;277:1224-8.
50. Dong BJ, Hauck WW, Gambertoglio JG, Gee L, White JR, Bubp JL, Greenspan FS. Bioequivalence of generic and brand-name levothyroxine products in the treatment of hypothyroidism. JAMA. 1997;277:1205-13.
51. Rennie D. Thyroid storm. JAMA. 1997;277:1238-43.
52. Boyd K. Commentary: Early discontinuation violates Helsinki principles. BMJ. 2001;322:605-6.
53. Evans S, Pocock S. Societal responsibilities of clinical trial sponsors. Lack of a commercial pay off is not a legitimate reason for stopping a trial. BMJ. 2001;322:569-70.
54. Lievre M, Menard J, Bruckert E, Cogneau J, Delahaye F, Girai P, Leitersdorf E, Luc G, Masana L, Moulin P, Passa P, Pouchain D, Siest G. Premature discontinuation of clinical trial for reasons not related to efficacy, safety, or feasability. BMJ. 2001;322:603-5.
55. Berenson A. Medical journal criticizes Merck over Vioxx data. NY Times. 2005 Dec 9;Sect A:1, C:13.
56. Bero LA. Tobacco industry manipulation of research. Public Health Rep. 2005;120:200-8.
57. Dyer C. Consultant struck off over research fraud. BMJ. 1997;315:205.
58. Dyer C. Drug company fined 2.2 million pounds for abusing its dominant position. BMJ. 2002;324:188.
59. Dyer O. GMC finds GPs guilty of fraud. BMJ. 1994;308:1122.
60. Egilman D, Wallace W, Hom C. Corporate corruption of medical literature: asbestos studies concealed by W.R. Grace & Co. Account Res. 1998;6:127-47.
61. Freestone DS, Mitchell H. Inappropriate publication of trial results and potential for allegations of illegal share dealing. BMJ. 1993;306:1112-4.
62. Gibson L. Adverse reaction reports may be vulnerable to manipulation. BMJ. 2005;330:1287.
63. Giles J. Industry money skews drug overviews. Nature. 2005;437:458-9.
64. Gould M. Drugs company makes false claims over bedwetting drug. BMJ. 2002;324:9.
65. Gruning T, Gilmore AB, McKee M. Tobacco industry influence on science and scientists in Germany. Am J Public Health. 2006;96:20-32.
66. Hoeksema HL, Troost J, Grobbee DE, Wiersinga WM, van Wijmen FC, Klasen EC. Fraud in a pharmaceutical trial. Lancet. 2000;356:1773.
67. Levine J, Gussow JD, Hastings D, Eccher A. Authors' financial relationships with the food and beverage industry and their published positions on the fat substitute olestra. Am J Public Health. 2003;93:664-9.
68. Nolan KJ. Pharmaceutical companies liable for fraudulent research by subcontractors. Drug Discov Today. 2004;9:153-4.
69. Schick S, Glantz S. Scientific analysis of second-hand smoke by the tobacco industry, 1929-1972. Nicotine Tob Res. 2005;7:591-612.
70. Schiermeier Q. Novartis goes public with fraud dismissal. Nature. 1998; 392:319.
71. Schoen EJ. Blood lead levels, scientific misconduct and the Needleman case. 2. The critics' arguments. Am J Public Health. 1996;86:112-5.
72. Tong EK, England L, Glantz SA. Changing conclusions on secondhand smoke in a sudden infant death syndrome review funded by the tobacco industry. Pediatrics. 2005;115:e356-66.
73. Tuffs A. German doctors face investigation in drugs scandal. BMJ. 2002;324:693.
74. Wadman M. $100m payout after drug data withheld. Nature. 1997;388:703.
75. Waxman HA. The lessons of Vioxx - drug safety and sales. N Engl J Med. 2005;352:2576-8.
76. Culliton BJ. Coping with fraud: the Darsee Case. Science. 1983;220:31-5.
77. Kintisch E. Scientific misconduct. Researcher faces prison for fraud in NIH grant applications and papers. Science. 2005;307:1851.
78. Dahlberg JE, Mahler CC. The Poehlmancase: running away from the truth. Sci Eng Ethics. 2006;12:157-73.